Douglas Epps
Family Medicine · Stockbridge, GANPI 1518957372
Payments from drug & device makers
Across 97 payments — averaging $27.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$470
- Medtronic$340
- Xeris Pharmaceuticals, Inc.$298
- Lilly USA, LLC$286
- Corcept Therapeutics$254
- Boehringer Ingelheim$126
- plus $874 from 14 others
What the payments were for
- Food & beverage$2,62899%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $470 |
| Medtronic | 5 | $340 |
| Xeris Pharmaceuticals, Inc. | 14 | $298 |
| Lilly USA, LLC | 14 | $286 |
| Corcept Therapeutics | 9 | $254 |
| Boehringer Ingelheim | 6 | $126 |
| Bayer | 6 | $124 |
| Cequr Corporation | 2 | $123 |
| Boston Scientific | 3 | $117 |
| Amgen | 5 | $101 |
| Radius Health, Inc. | 3 | $100 |
| Ascendis Pharma Endocrinology Inc | 3 | $70 |
| Mannkind Corporation | 3 | $67 |
| Novartis | 3 | $50 |
| Verity Pharmaceuticals Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| AbbVie | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$262
- Wegovy$125
- Ozempic$125
- CeQur Simplicity$106
How this compares
$2,648 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 79 | $74,671 |
| OzempicSemaglutide | 33 | $39,025 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $5,110 |
| Novolog FlexpenInsulin Aspart | 12 | $3,657 |
| Cinacalcet Hcl | 14 | $700 |
| Methimazole | 15 | $187 |
| Levothyroxine Sodium | 32 | $178 |
| Rosuvastatin Calcium | 11 | $173 |
| Atorvastatin Calcium | 11 | $123 |
| Metformin Hcl | 24 | $87 |
| Metformin Hcl ErMetformin Hcl | 11 | $78 |
| Glipizide ErGlipizide | 11 | $74 |
| Glimepiride | 13 | $67 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $126 | $74,67179 claims |
| Novo NordiskOzempic | $470 | $39,02533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Stockbridge
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.